Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia.
Antibody
COVID-19
SARS-CoV-2
Saudi Arabia
Seroprevalence
Journal
Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
29
01
2021
revised:
18
03
2021
accepted:
11
04
2021
pubmed:
13
6
2021
medline:
1
7
2021
entrez:
12
6
2021
Statut:
ppublish
Résumé
Estimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for a better evaluation of the virus spread and monitoring the progress of COVID-19 pandemic in a population. In the Kingdom of Saudi Arabia (KSA), SARS-CoV-2 seroprevalence has been reported in specific regions, but an extensive nationwide study has not been reported. Here, we report a nationwide study to determine the prevalence of SARS-CoV-2 in the population of KSA during the pandemic, using serum samples from healthy blood donors, non-COVID patients and healthcare workers (HCWs) in six different regions of the kingdom, with addition samples from COVID-19 patients. A total of 11,703 serum samples were collected from different regions of the KSA including; 5395 samples from residual healthy blood donors (D); 5877 samples from non-COVID patients collected through residual sera at clinical biochemistry labs from non-COVID patients (P); and 400 samples from consented HCWs. To determine the seroprevalence of SARS-CoV-2, all serum samples, in addition to positive control sera from RT-PCR confirmed COVID-19 patients, were subjected to in-house ELISA with a sample pooling strategy, which was further validated by testing individual samples that make up some of the pools, with a statistical estimation method to report seroprevalence estimates. Overall (combining D and P groups) seroprevalence estimate was around 11% in Saudi Arabia; and was 5.1% (Riyadh), 1.5% (Jazan), 18.4% (Qassim), 20.8% (Hail), 14.7% (ER; Alahsa), and 18.8% in Makkah. Makkah samples were only D group and had a rate of 24.4% and 12.8% in the cities of Makkah and Jeddah, respectively. The seroprevalence in Saudi Arabia across the sampled areas would be 12 times the reported COVID-19 infection rate. Among HCWs, 7.5% (4.95-10.16 CI 95%) had reactive antibodies to SARS-CoV-2 without reporting any previously confirmed infection. This was higher in HCWs with hypertension. The study also presents the demographics and prevalence of co-morbidities in HCWs and subset of non-COVID-19 population. Our study estimates the overall national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions. This indicates the prevalence of asymptomatic or mild unreported COVID-19 cases.
Sections du résumé
BACKGROUND
BACKGROUND
Estimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for a better evaluation of the virus spread and monitoring the progress of COVID-19 pandemic in a population. In the Kingdom of Saudi Arabia (KSA), SARS-CoV-2 seroprevalence has been reported in specific regions, but an extensive nationwide study has not been reported. Here, we report a nationwide study to determine the prevalence of SARS-CoV-2 in the population of KSA during the pandemic, using serum samples from healthy blood donors, non-COVID patients and healthcare workers (HCWs) in six different regions of the kingdom, with addition samples from COVID-19 patients.
METHODS
METHODS
A total of 11,703 serum samples were collected from different regions of the KSA including; 5395 samples from residual healthy blood donors (D); 5877 samples from non-COVID patients collected through residual sera at clinical biochemistry labs from non-COVID patients (P); and 400 samples from consented HCWs. To determine the seroprevalence of SARS-CoV-2, all serum samples, in addition to positive control sera from RT-PCR confirmed COVID-19 patients, were subjected to in-house ELISA with a sample pooling strategy, which was further validated by testing individual samples that make up some of the pools, with a statistical estimation method to report seroprevalence estimates.
RESULTS
RESULTS
Overall (combining D and P groups) seroprevalence estimate was around 11% in Saudi Arabia; and was 5.1% (Riyadh), 1.5% (Jazan), 18.4% (Qassim), 20.8% (Hail), 14.7% (ER; Alahsa), and 18.8% in Makkah. Makkah samples were only D group and had a rate of 24.4% and 12.8% in the cities of Makkah and Jeddah, respectively. The seroprevalence in Saudi Arabia across the sampled areas would be 12 times the reported COVID-19 infection rate. Among HCWs, 7.5% (4.95-10.16 CI 95%) had reactive antibodies to SARS-CoV-2 without reporting any previously confirmed infection. This was higher in HCWs with hypertension. The study also presents the demographics and prevalence of co-morbidities in HCWs and subset of non-COVID-19 population.
INTERPRETATION
CONCLUSIONS
Our study estimates the overall national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions. This indicates the prevalence of asymptomatic or mild unreported COVID-19 cases.
Identifiants
pubmed: 34118732
pii: S1876-0341(21)00098-8
doi: 10.1016/j.jiph.2021.04.006
pmc: PMC8188888
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
832-838Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
J Clin Invest. 2020 Oct 1;130(10):5235-5244
pubmed: 32634129
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Clin Infect Dis. 2021 Nov 2;73(9):e2932-e2942
pubmed: 32856707
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
J Med Virol. 2021 Mar;93(3):1526-1531
pubmed: 32869865
Life Sci. 2020 Oct 1;258:118202
pubmed: 32758625
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Viruses. 2020 Dec 04;12(12):
pubmed: 33291713
bioRxiv. 2020 Dec 18;:
pubmed: 33442687
Cureus. 2020 Sep 6;12(9):e10285
pubmed: 33047077
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Healthcare (Basel). 2021 Jan 05;9(1):
pubmed: 33466554
Diagn Microbiol Infect Dis. 2021 Mar;99(3):115273
pubmed: 33296851
Clin Infect Dis. 2021 Aug 2;73(3):e531-e539
pubmed: 32745196
Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):745-755
pubmed: 33549450
J Infect Public Health. 2020 Dec;13(12):1833-1839
pubmed: 32788073
Anaesthesia. 2020 Jul;75(7):976-977
pubmed: 32339251
Lancet Infect Dis. 2021 Apr;21(4):473-481
pubmed: 33338441
Saudi J Biol Sci. 2021 Mar;28(3):1697-1701
pubmed: 33519277
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974